Navigation Links
Angiotech announces results for the fourth quarter ended December 31, 2007
Date:2/14/2008

Dec. 31, 2007 Dec. 31, 2006

------------------------------

Stock-based compensation (2,642) (3,609)

Termination and reorganization costs

related to the integration of AMI (8,365) (1,879)

Litigation expenses relating to

defending intellectual property claims (5,611) (11,774)

Non-recurring supply / distribution

agreement termination costs (250) -

---------------------------------------------------------------------

(16,868) (17,262)

---------------------------------------------------------------------

g. Amortization of acquisition related intangible assets and medical

technologies.

h. Non-recurring in-process research and development expense relating to

payments made to licensors and collaborators, including CombinatorX

Inc. and Rex Medical Inc.

i. Foreign exchange fluctuations on foreign currency net monetary

assets.

j. Write off of uncollectible receivable and write off of certain

capitalized costs, net of gain realized on recovery of investments.

k. Gain on sale of Palo Alto building and gain on sale related to

disposition of Neodisc technology rights to NuVasive.

l. Amortization of deferred financing costs.

m. Net impact of loss and gain on redemption of investments of common

share holdings in Orthovita Inc. and NuVasive, Inc., respectively.

n. Net impact of gain on redemption of investments and loss on write

down of investments.

o. Loss on extinguishment of term loans related to our December 2006

senior floating rate note refinancing.

p. Tax effects of adjustments a. th
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email: